PRGO Stock Recent News
PRGO LATEST HEADLINES
Perrigo (PRGO) reports encouraging second-quarter 2023 results. Management reaffirms the financial guidance for 2023.
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Perrigo (PRGO) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.43 per share a year ago.
DUBLIN , July 25, 2023 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call beginning at 8:30 A.M. (EST). Separately, President and CEO, Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Canaccord Genuity 43rd Annual Growth Conference in Boston on Wednesday, August 9 th at 10:30 A.M.
Perrigo's birth control pill, Opill, can now be sold without a prescription. It'll likely start to nibble on the market shares of most other contraceptive methods.
Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.
Perrigo (NYSE: PRGO ) stock is rising on Friday as investors react to the company's over-the-counter birth control pill getting FDA approval. This is a major win for Perrigo stock as it marks the first time that the FDA has approved a daily over-the-counter birth control pill.
The FDA just approved the first over-the-counter birth control pill -- Perrigo's Opill. There could be a significant demand for the OTC oral contraceptive.
Ibis Reproductive Health President Kelly Blanchard spoke with Yahoo Finance Live anchor Rachelle Akuffo about the FDA approval of Perrigo's Opill to be sold over the counter in the United States.
Yahoo Finance Live anchors Julie Hyman and Brad Smith break down the U.S. Food and Drug Administration approving Perrigo over-the-counter birth control pill named OPill. It is the first approval of an over-the-counter oral contraceptive in the United States.